ha, ha. You mean I shouldn't mention another COVID-19 ARDS trial by competitor company in a thread titled: "The competition to Remestemcel-L in COVID-19"?
I don't think their product is anywhere near at the same readiness and development stage but I wrote t'hey are at the same stage of trials'.
I just want some opinions from the learned here on the why there would be a differences in primary endpoints and more detail on their stage of product development, if anyone has followed their history.
MSB Price at posting:
$3.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)